Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Anti-leukemia and anti-viral T-cell immunotherapy of photodepleted allogeneic T-cells

Denis-Claude Roy • 24 Mar 2019
EBMT 2019
General ATIR101

Denis-Claude Roy, MD, FRCPC, from the University of Montreal, Montreal, Canada, speaks about potential methods to minimize the occurance of graft-versus-host disease (GvHD) using anti-leukemia and anti-viral T-cell immunotherapy of photodepleted allogeneic T-cells. This interview took place at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Denis-Claude Roy

3:25
ATIR101 after haplo HSCT proves promising
Denis-Claude Roy • 7 Dec 2019
1:42
T-cell depleted haploidentical SCT followed by ATIR101 vs. T-cell replete HSCT plus chemo
Denis-Claude Roy • 24 Mar 2019
2:08
Eradicating GvHD after haploidentical stem cell transplant
Denis-Claude Roy • 18 Mar 2018
1:56
Implications for a technique which eliminates GvHD
Denis-Claude Roy • 18 Mar 2018

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals